FDA Approves 2nd Alzheimer's Drug, Despite Safety Concerns |

FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second Alzheimer's drug, lecanemab, despite reports of rare brain bleeds linked to use

Related Keywords

Ohio , United States , Northwestern University , Illinois , Chicago , Americans , Howard Fillit , Los Angeles , Rudolph Castellani , Marwan Sabbagh , Babak Tousi , Sarah Kremen , Billy Dunn , Cleveland Clinic Center , Northwestern University Medical Center , Brain Health , Office Of Neuroscience , Drug Administration On , Institute For Clinical , Alzheimer Drug Discovery Foundation , Alzheimer Disease Clinical Trials Program At Cedars , Clinical Trials Program , Healthday News , Drug Administration , Drug Evaluation , Disease Clinical Trials Program , Drug Discovery Foundation , Cleveland Clinic , New England Journal , Science Insider , Northwestern Medicine , Thenew York Times , Economic Review , Consumer News ,